source
- Study finds malaria antibody L9LS reduces vaccine response in infantsResearchers in Mali tested the monoclonal antibody L9LS in infants to see if it could protect against malaria and complement the R21 vaccine. The trial showed L9LS provided about 78% protection ov…
- Sanofi receives FDA clearance for Infilbray, first pill to treat neurological symptoms of Type 3 Gaucher diseaseSanofi received FDA clearance for Infilbray, a once-daily pill for Type 3 Gaucher disease in adults and children weighing at least 15 kilograms. The drug, inherited from Sanofi’s 2011 acquisition…